Every month, MassBio spotlights a member company and the great work they’re doing to advance the life sciences industry and support the patients we serve. This month we spoke with Bhavin Busa, Director of Statistical Programming and Data Analytics for Vita Data Sciences.
Tell us about your organization and your current initiatives
Vita Data Sciences is a division of Softworld, Inc. and is a leading clinical data services and technology solutions provider. Our mission is to expedite the clinical trial development process by providing best-in-class data review, analysis, reporting, and submission services. Our team of Biostatisticians and Data Scientists strive to ensure that our clients have access to their data from “Day 1” enabling them to make faster decisions on their ongoing clinical trials. We work hard to ensure we provide top notch services and products, while also staying nimble enough to quickly adjust to changes in the industry.
How does your organization’s activities help patients now and into the future?
“Think Data! Think Patient!” is the Vita Data Sciences mantra. In the world of drug development and life sciences, sometimes the focus is turned towards budgets, and cost. The efforts and passion of our team help companies stay within their budgets and timelines, while also maximizing the results of their investment in data analytics.
Everybody has a family member or friend that is affected by disease or illness. I am proud, that in some humble way, we get to be part of the effort to expedite drugs to the marketplace that will help so many people for years to come.
What do you see as the biggest challenge facing the life sciences industry today, and what’s your advice for overcoming?
The biggest challenge facing our niche of the life sciences industry is the increasing rigidity and inflexibility of the services industry. Most of the time when we meet with our partners, we find that the current strategy that has been put in place is not necessarily the most effective one for them. There are many reasons why this happens, but the end-result is usually a less efficient and more costly trial.
The best advice we can give is to collaborate with your partners to truly understand their company and science before you start to give any recommendations on the best way to set up a partnership. No two organizations are the same and they all have their own unique challenges within them. The real value-add, from our perspective, is to create a solution that works effectively and efficiently for their team versus one that is commonly done or is the “industry standard.”
What’s next for your organization / what are you focused on in the coming year?
The ongoing focus for Vita Data Sciences is to continue to grow and expand our team and operations in Massachusetts, as well as offshore. We are very fortunate to be located in the Greater Boston area, which is constantly at the forefront of innovation in the drug development industry. As clinical trials remain the gold standard for drug approval, the development of new drugs and devices plays a crucial role in human well-being. We aim to expand our current partnerships and explore new relationships with life science companies that share in achieving our objective of making people’s lives better.
Aside from internal expansion, we are also heavily investing in research and development for our various Data Analytics platforms. We will be continuing to present our solutions at various forums and conferences this year (PharmaSUG, PhUSE, DIA) along with VDS webinars and networking sessions. Our ultimate goal is to provide an innovative and collaborative solution that our partners can use across all parts of their clinical trials.
If you would like to learn more about our team and service offerings, please visit our site at http://www.vitadatasciences.com/.
If you’re interested in being featured in MassBio’s Member Spotlight, please see guidelines here.